Flow-injection analysis for meloxicam based on tris(2,2'-bipyridine) ruthenium(II)-Ce(IV) chemiluminescent system.
It was found that meloxicam could enhance the chemiluminescence (CL) of the tris(2,2'-bipyridine) ruthenium(II)-Ce(IV) system in the medium of sulfate acid. Based on this phenomenon a new flow-injection system with chemiluminescent detection has been proposed for determination of meloxicam. Under optimum conditions, meloxicam had a good linear relationship with the CL intensity in the concentration range of 6.0 10(-4) to 1.0 microg/mL and the detection limit was 3.7 x 10(-4 )microg/mL. The proposed method was applied to detect meloxicam in tablets and a satisfactory recovery was obtained. The possible mechanism for this CL system is also discussed in this paper.
Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of meloxicam in human plasma.
Meloxicam was quantified in human plasma after a single 15 mg oral dose of the drug was given to 26 healthy volunteers. An Applied Biosystems Sciex API 2000 triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode, using TurboIonSpray (TIS) in the positive ion mode, was used. Protein precipitation with acetonitrile was followed by C(18) reverse phase liquid chromatography and tandem mass spectrometry. The mean recovery for meloxicam was 92% with a lower limit of quantification of 8.96 ng/ml. Piroxicam was used as the internal standard. This assay method makes use of the increased sensitivity and selectivity of tandem mass spectrometry (MS-MS) detection to allow for a more rapid (extraction and chromatography) and selective method for the determination of meloxicam in human plasma than has previously been described.
SIMULTANEOUS HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS OF NON-STEROIDAL ANTI-INFLAMMATORY OXICAMS IN PHARMACEUTICAL PREPARATIONS
A simple and rapid isocratic high-performance liquid chromatographic method has been developed for the simultaneous analysis of the non-steroidal anti-inflammatory drugs tenoxicam, piroxicam, meloxicam, and lornoxicam using isoxicam as an internal standard. The analyte was chromatographed using a Lichrosphere RP18 column, a Tris acetic acid buffer-tetrabutylammonium reagent-tetrahydrofuran-acetonitrile as the mobile phase, and UV detection at 360 nm. The separation obtained was very good. The method was applied to pharmaceutical formulations containing a single active ingredient and was shown to be linear, sensible, accurate, and reproducible. A very small modification of the mobile phase enabled the separation of tenoxicam, piroxicam, isoxicam, cinnoxicam,meloxicam, and lornoxicam with symmetrical and well resolved peaks.